Contribution of Intestine, Bone, Kidney, and Dialysis to Extracellular Fluid Calcium Content

被引:61
作者
Bushinsky, David A. [1 ,2 ,3 ]
机构
[1] Univ Rochester, Med Ctr, Div Nephrol, Rochester, NY 14642 USA
[2] Univ Rochester, Dept Med, Sch Med, Rochester, NY 14642 USA
[3] Univ Rochester, Dept Physiol & Pharmacol, Sch Med, Rochester, NY 14642 USA
来源
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY | 2010年 / 5卷
基金
美国国家卫生研究院;
关键词
PARATHYROID-HORMONE SECRETION; SERUM 1,25-(OH)2-VITAMIN-D CONCENTRATIONS; CHRONIC METABOLIC-ACIDOSIS; SKELETAL RESISTANCE; VASCULAR CALCIFICATION; RENAL-FAILURE; VITAMIN-D; MINERAL DENSITY; SECONDARY HYPERPARATHYROIDISM; 1,25(OH)2D3 RESPONSE;
D O I
10.2215/CJN.05970809
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
100201 [内科学]; 100221 [泌尿外科学];
摘要
Calcium (Ca) balance is the net of Ca intake and output from the body over a period of time. The concept of Ca balance does not consider the redistribution of Ca that often occurs in patients with chronic kidney disease (CKD), especially those who are on dialysis, which is often in the form of soft tissue and/or vascular calcification. In this article, we consider movement of Ca with respect to the extracellular fluid (ECF) and develop a mathematical formulation for Ca homeostasis with respect to the ECF that includes input and output from the diet, the bone, the kidney, and dialysis. We consider calcium homeostasis in healthy individuals and in patients with excess parathyroid hormone, excess 1,25-dihydroxyvitamin D-3, and metabolic acidosis; patients who have CKD and are not on dialysis; and, finally, patients who have CKD and are on dialysis. On the basis of a number of assumptions, dialysis patients with a daily intake of >37.5 mmol of elemental Ca (1.5 g) have movement of Ca into the ECF even without supplemental activated vitamin D. Addition of activated vitamin D, which increases intestinal Ca absorption and can increase resorption of Ca from bone, leads to the movement of Ca into the ECF at virtually all levels of intake; however, there are numerous unanswered questions regarding Ca homeostasis in patients with CKD, including how much of the Ca, administered as a phosphate binder, is absorbed and what is the fate of this absorbed Ca. Until these pressing questions are answered with well-designed experiments, we do not know whether we are doing more harm than good for our dialysis patients by administering additional Ca as a phosphate binder, especially when they also receive activated vitamin D. Clin J Am Soc Nephrol 5: S12-S22, 2010. doi: 10.2215/CJN.05970809
引用
收藏
页码:S12 / S22
页数:11
相关论文
共 134 条
[1]
CALCIURIA OF INCREASED FIXED ACID PRODUCTION IN HUMANS - EVIDENCE AGAINST A ROLE FOR PARATHYROID-HORMONE AND 1,25(OH)2-VITAMIN-D [J].
ADAMS, ND ;
GRAY, RW ;
LEMANN, J .
CALCIFIED TISSUE INTERNATIONAL, 1979, 28 (03) :233-238
[2]
EFFECTS OF CALCITRIOL ADMINISTRATION ON CALCIUM-METABOLISM IN HEALTHY-MEN [J].
ADAMS, ND ;
GRAY, RW ;
LEMANN, J ;
CHEUNG, HS .
KIDNEY INTERNATIONAL, 1982, 21 (01) :90-97
[3]
Association of Serum Phosphate with Vascular and Valvular Calcification in Moderate CKD [J].
Adeney, Kathryn L. ;
Siscovick, David S. ;
Ix, Joachim H. ;
Seliger, Stephen L. ;
Shlipak, Michael G. ;
Jenny, Nancy S. ;
Kestenbaum, Bryan R. .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2009, 20 (02) :381-387
[4]
Vascular Calcification in Uremia: What Is New and Where Are We Going? [J].
Al-Aly, Ziyad .
ADVANCES IN CHRONIC KIDNEY DISEASE, 2008, 15 (04) :413-419
[5]
INTRAVENOUS CALCITRIOL IN THE TREATMENT OF REFRACTORY OSTEITIS FIBROSA OF CHRONIC RENAL-FAILURE [J].
ANDRESS, DL ;
NORRIS, KC ;
COBURN, JW ;
SLATOPOLSKY, EA ;
SHERRARD, DJ .
NEW ENGLAND JOURNAL OF MEDICINE, 1989, 321 (05) :274-279
[6]
ARGILES A, 1995, NEPHROL DIAL TRANSPL, V10, P2083
[7]
HYPERPARATHYROIDISM AND RENAL-FAILURE [J].
ARNAUD, CD .
KIDNEY INTERNATIONAL, 1973, 4 (02) :89-95
[8]
Bickle DA., 2008, Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, P141
[9]
Guidelines for the Management of Asymptomatic Primary Hyperparathyroidism: Summary Statement from the Third International Workshop [J].
Bilezikian, John P. ;
Khan, Aliya A. ;
Potts, John T., Jr. .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2009, 94 (02) :335-339
[10]
Primary hyperparathyroidism: new concepts in clinical, densitometric and biochemical features [J].
Bilezikian, JP ;
Brandi, ML ;
Rubin, M ;
Silverberg, SJ .
JOURNAL OF INTERNAL MEDICINE, 2005, 257 (01) :6-17